FATE
Income statement / Annual
Last year (2024), Fate Therapeutics, Inc.'s total revenue was $13.63 M,
a decrease of 78.55% from the previous year.
In 2024, Fate Therapeutics, Inc.'s net income was -$186.26 M.
See Fate Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$13.63 M |
$63.53 M |
$96.30 M |
$55.85 M |
$31.43 M |
$10.68 M |
$4.74 M |
$4.11 M |
$4.40 M |
$2.43 M |
| Cost of Revenue |
$0.00
|
$157.19 M
|
$13.76 M
|
$5.85 M
|
$125.62 M
|
$0.00
|
$56.02 M
|
$34.36 M
|
$26.45 M
|
$19.86 M
|
| Gross Profit |
$13.63 M
|
-$93.65 M
|
$82.54 M
|
$50.00 M
|
-$94.19 M
|
$10.68 M
|
-$51.28 M
|
-$30.25 M
|
-$22.05 M
|
-$17.43 M
|
| Gross Profit Ratio |
1
|
-1.47
|
0.86
|
0.9
|
-3
|
1
|
-10.82
|
-7.37
|
-5.01
|
-7.17
|
| Research and Development Expenses |
$135.00 M
|
$172.60 M
|
$320.45 M
|
$215.52 M
|
$125.62 M
|
$87.77 M
|
$56.02 M
|
$34.36 M
|
$26.45 M
|
$19.86 M
|
| General & Administrative Expenses |
$74.17 M
|
$81.45 M
|
$84.23 M
|
$57.32 M
|
$33.90 M
|
$23.64 M
|
$15.81 M
|
$11.87 M
|
$9.91 M
|
$10.35 M
|
| Selling & Marketing Expenses |
$0.00
|
$15.41 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$74.17 M
|
$96.86 M
|
$84.23 M
|
$57.32 M
|
$33.90 M
|
$23.64 M
|
$15.81 M
|
$11.87 M
|
$9.91 M
|
$10.35 M
|
| Other Expenses |
$14.74 M
|
-$172.60 M
|
-$13.76 M
|
-$5.85 M
|
-$125.62 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$223.91 M
|
$96.86 M
|
$390.93 M
|
$266.99 M
|
$33.90 M
|
$111.41 M
|
$71.83 M
|
$46.23 M
|
$36.37 M
|
$30.21 M
|
| Cost And Expenses |
$223.91 M
|
$254.04 M
|
$404.69 M
|
$272.84 M
|
$159.52 M
|
$111.41 M
|
$71.83 M
|
$46.23 M
|
$36.37 M
|
$30.21 M
|
| Interest Income |
$17.29 M
|
$17.19 M
|
$5.84 M
|
$1.31 M
|
$2.40 M
|
$4.33 M
|
$2.19 M
|
$559.00 K
|
$138.00 K
|
$10.00 K
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$1.75 M
|
$1.70 M
|
$1.27 M
|
$1.64 M
|
$2.22 M
|
| Depreciation & Amortization |
$18.96 M
|
$18.28 M
|
$13.76 M
|
$5.85 M
|
$3.09 M
|
$2.19 M
|
$1.20 M
|
$971.00 K
|
$881.00 K
|
$687.00 K
|
| EBITDA |
-$176.58 M |
-$172.23 M |
-$294.63 M |
-$211.14 M |
-$125.00 M |
-$94.20 M |
-$63.70 M |
-$40.71 M |
-$30.94 M |
-$27.09 M |
| EBITDA Ratio |
-12.95
|
-2.71
|
-3.06
|
-3.78
|
-3.98
|
-8.82
|
-13.44
|
-9.92
|
-7.03
|
-11.14
|
| Operating Income Ratio |
-15.43
|
-3
|
-3.2
|
-3.89
|
-4.07
|
-9.43
|
-14.15
|
-10.26
|
-7.26
|
-11.43
|
| Total Other Income/Expenses Net |
$24.01 M
|
$29.58 M
|
$26.67 M
|
$4.84 M
|
-$45.30 M
|
$2.58 M
|
$494.00 K
|
-$827.00 K
|
-$1.50 M
|
-$2.21 M
|
| Income Before Tax |
-$186.26 M
|
-$160.93 M
|
-$281.72 M
|
-$212.15 M
|
-$173.39 M
|
-$98.15 M
|
-$66.60 M
|
-$42.95 M
|
-$33.46 M
|
-$29.99 M
|
| Income Before Tax Ratio |
-13.66
|
-2.53
|
-2.93
|
-3.8
|
-5.52
|
-9.19
|
-14.05
|
-10.46
|
-7.6
|
-12.34
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$297.00 K
|
$0.00
|
$0.00
|
| Net Income |
-$186.26 M
|
-$160.93 M
|
-$281.72 M
|
-$212.15 M
|
-$173.39 M
|
-$98.15 M
|
-$66.60 M
|
-$42.95 M
|
-$33.46 M
|
-$29.99 M
|
| Net Income Ratio |
-13.66
|
-2.53
|
-2.93
|
-3.8
|
-5.52
|
-9.19
|
-14.05
|
-10.46
|
-7.6
|
-12.34
|
| EPS |
-1.64 |
-1.64 |
-2.91 |
-2.24 |
-2.1 |
-1.43 |
-1.19 |
-1.02 |
-1.05 |
-1.18 |
| EPS Diluted |
-1.64 |
-1.64 |
-2.91 |
-2.24 |
-2.1 |
-1.43 |
-1.19 |
-1.02 |
-1.05 |
-1.18 |
| Weighted Average Shares Out |
$113.69 M
|
$98.41 M
|
$96.83 M
|
$94.75 M
|
$82.39 M
|
$68.19 M
|
$56.20 M
|
$41.98 M
|
$31.75 M
|
$25.48 M
|
| Weighted Average Shares Out Diluted |
$113.69 M
|
$98.41 M
|
$96.83 M
|
$94.75 M
|
$82.39 M
|
$68.19 M
|
$56.20 M
|
$41.98 M
|
$31.75 M
|
$25.48 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
